Search

Search Constraints

You searched for: Author/Creator Ferracane, C.

Search Results

1. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021)

2. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021)

3. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020)

4. P.02.4 EFFECTIVENESS OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR OUTCOMES: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). Issue 2 (15th March 2018)

5. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (September 2021)

6. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (March 2023)

7. T.10.1 SAFETY AND EFFECTIVENESS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD DATA FROM TOFA-UC, A SN-IBD STUDY. (March 2023)

8. T04.01.19 USTEKINUMAB IN CROHN'S DISEASE: REAL-WORLD OUTCOMES FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD) – PRELIMINARY RESULTS. (1st October 2020)